# TRANSCRIPT — R-LIT
model: gpt-5.5-2026-04-23 | reasoning_effort: high | retrieval: targeted-retrieval | web: DISABLED (no hosted tools) | started: 2026-06-03T22:06:23
docs available: ['INDEX', 'proof', 'ref01', 'ref02', 'ref03', 'ref04', 'ref06', 'ref07', 'ref08', 'ref09', 'ref10', 'ref11', 'ref12', 'ref13', 'ref14', 'ref15', 'ref17', 'ref18', 'ref19', 'ref20', 'ref21', 'ref22', 'ref23', 'ref24']

===== DEVELOPER MESSAGE =====
You are running inside an OFFLINE evaluation harness. You have NO internet access and NO shell. Access documents ONLY through these tools:
- list_docs(): list available document names.
- search_doc(name, query): find passages matching a query (regex/text) with surrounding context.
- read_doc(name, offset, length): read a document, optionally a bounded window.
- write_note(name, content): optional scratch memory.
Documents: 'proof' (the submitted manuscript proof, including its bound supplementary appendix), 'INDEX' (maps each cited reference number to its source), and 'ref01'..'ref24' (full text of each cited reference). References 5 and 16 are NOT provided (no ref05/ref16). When the instructions refer to the manuscript PDF, 'pdfs/INDEX.md', or a reference's PDF, use the matching name (reference 7 -> 'ref07').

EFFICIENCY (important): you are checking citations, which is a targeted task. Do NOT read entire references into memory. For each claim, use search_doc(cited_ref, key terms) to locate where that reference addresses it, then read_doc(cited_ref, offset, length) to read the surrounding passage for context. read_doc returns at most 30,000 characters per call; page with offset only if you genuinely need more. You may read the 'proof' more broadly to enumerate its citations. Retrieve only what you need.

===== USER INSTRUCTION (verbatim) =====
You are serving as a peer reviewer for a general medical journal (the BMJ tier). You have been sent a manuscript reporting a randomized controlled trial and PDFs of the references it cites. You do not have the raw data or the analysis code — review what you have been given, as a reviewer at submission would. Your job is to produce a rigorous, fair, and specific peer-review report that helps the editors decide whether the work is sound and what revisions it needs.

You have no internet access. You are reviewing this manuscript pre-publication; treat the trial's results elsewhere, this paper, and any outside commentary as unavailable. The references the manuscript cites are provided as PDFs in `pdfs/` (an index maps each to its reference number) — consult those directly rather than relying on memory when you need to check what a cited source says.

Ground every point in the manuscript or a cited reference. Do not raise generic concerns you cannot tie to something specific in these materials. Distinguish issues that are major (could change conclusions or require new analysis) from minor (clarity, reporting). Be concrete: cite sections, tables, figures, page numbers, and the specific sentence at issue.

Produce your report in the format specified at the end of these instructions.

## Your role

Your focus is whether the manuscript's citations are accurate and fairly used. The PDFs of the cited references are provided, mapped to reference numbers in an index file (22 of 24 are present; two are unavailable — for any claim resting on a missing source, report it as "uncheckable — source PDF not provided" rather than guessing). For the manuscript's substantive citations — especially those supporting the rationale, the choice of intervention and dose, the comparison to prior trials, and any claim of consistency or contradiction with earlier evidence — open the cited source and check that it actually says what the manuscript attributes to it. Flag: citations that don't support the claim, claims that overstate or misread the source, relevant prior evidence cited selectively or one-sidedly, and any place a key claim has no supporting citation. Quote the relevant sentence from the cited PDF when you flag a mismatch. Note which citations you could not check because the source PDF was not provided.

## Your materials

You have been given exactly these, and nothing else (no internet, no raw data, no analysis code, no published version of this paper, no other commentary):

1. **The submitted manuscript proof** — `inputs/27_jan_2026_bmj-2026-089636_proof_hi.pdf`. This is the complete submission. It **includes the supplementary appendix** bound at the end (table of contents plus supplementary tables S1–S14 and supplementary figures).
2. **The cited references** — the manuscript cites 24 references; their PDFs are in `pdfs/`, mapped reference-number → file in `pdfs/INDEX.md`. **22 of the 24 are present.** Two are unavailable: **reference 5 and reference 16** — for any claim resting on either, report it as "uncheckable — source PDF not provided." Read `pdfs/INDEX.md` first; it also notes one citation (reference 1) where the title as cited differs from the title of the provided source document — weigh that as a citation-accuracy point.

## Required output format

End your review with these sections, in this order:

1. **Summary** (3–5 sentences: what the trial did, your overall assessment).
2. **Major points** (numbered; each with the specific manuscript/reference location).
3. **Minor points** (numbered).
4. **Anything you verified that checked out** (numbered; what you confirmed against a cited source — so editors know what was checked, not just what failed).
5. **Editorial recommendation** (accept / minor revision / major revision / reject) **with one paragraph of justification.**
6. **What I could not assess** (limits of what you could check with the materials given — e.g., the two reference PDFs not provided).

===== FINAL OUTPUT =====
## 1. Summary

This manuscript reports a multicentre, double blind, placebo controlled, phase 3 randomized trial of 1 g intravenous tranexamic acid versus placebo, given after cord clamping with prophylactic oxytocin, among women with placenta praevia undergoing caesarean delivery in China. The trial found a statistically significant reduction in the composite primary outcome of calculated blood loss ≥1000 mL or red cell transfusion within 2 days, with similar reported serious adverse events. Overall, many core citations for global PPH burden, placenta praevia definitions, PAS classification, and the trial’s blood-loss formula check out. However, several citations in the rationale and discussion overgeneralise or mischaracterise the cited evidence, especially the baseline PPH risk in placenta praevia/PAS and the comparison with prior tranexamic acid trials.

## 2. Major points

1. **The cited source does not support the general PPH-incidence claim for placenta praevia and PAS.**  
   **Manuscript location:** Introduction, p 6, lines 147–150: “PPH occurs in approximately one-third of pregnancies complicated by placenta praevia, with the incidence escalating to 56% in cases co-existing with placenta accreta spectrum (PAS) disorders.4”  
   **Problem:** Reference 4 is not a general placenta praevia cohort and does not directly support the quoted claim as written. It is a highly selected retrospective study of **singleton pregnancies with anterior placenta previa, prior caesarean section, and prenatal suspicion of PAS**, focused on massive transfusion prediction. The abstract states: “A cohort of 430 individuals with APP, having undergone prior CS, and with prenatal suspicion of PAS… were retrospectively examined.” In Table 2, PPH is reported by massive-transfusion status: “Postpartum hemorrhage 76 (29.0%)” in the non-massive-transfusion group and “165 (98.2%)” in the massive-transfusion group; this totals about 56% in the selected cohort but is not the incidence “in cases co-existing with PAS disorders” generally. The “approximately one-third” figure appears to correspond to a subgroup within this selected cohort, not to all pregnancies complicated by placenta praevia.  
   **Revision needed:** Either cite a source that directly estimates PPH incidence in unselected placenta praevia and placenta praevia+PAS populations, or rephrase to make clear that these figures came from a selected anterior placenta praevia/prior caesarean/suspected PAS cohort.

2. **The prior tranexamic-acid evidence is characterised too simply as “low-risk” and the high-risk-benefit rationale needs more balanced wording.**  
   **Manuscript location:** Introduction, p 6, lines 155–162: “Tranexamic acid… has been shown to effectively reduce the incidence of PPH during caesarean delivery in low-risk populations.7… previous studies have predominantly enrolled participants from low-risk or mixed-risk (∼50% unscheduled caesarean delivery) populations… high-risk patients… may derive greater clinical benefit…9-11”  
   **Problem:** Reference 7 (TRAAP2) was not simply a low-risk trial. It included prespecified PPH-risk subgroups: the paper defines women “at risk for PPH” as those with “previous PPH, pregnancy-related hypertensive disorder, multiple pregnancy, or cesarean delivery during labor,” and reports 1710 women “At risk for PPH” and 2430 “Not at risk for PPH.” The TRAAP2 trial also found benefit only for its calculated/transfusion composite, while stating that tranexamic acid “did not result in lower incidences of clinical secondary outcomes related to blood loss.” Reference 11 is also not supportive of a general “high-risk patients may derive greater clinical benefit” assertion: WOMAN-2 enrolled women with moderate/severe anaemia and concluded, “giving tranexamic acid within 15 min of the umbilical cord being clamped did not reduce the risk of clinically diagnosed postpartum haemorrhage.”  
   **Revision needed:** Recast this paragraph to distinguish: (a) calculated blood-loss composite benefits in TRAAP2, (b) no reduction in death/transfusion in the MFMU trial, (c) Cochrane’s conclusion that most caesarean prophylaxis evidence was low-risk and insufficient for high-risk groups, and (d) the null high-risk anaemia findings in WOMAN-2. This would make the knowledge gap more accurate without overstating expected benefit.

3. **The statement that the trial’s NNTs are “substantially lower” than two prior caesarean trials is not supported for TRAAP2.**  
   **Manuscript location:** Discussion, p 12–13, lines 379–383: “the number needed to treat… was 19 for PPH… These values are substantially lower than those reported in two prior trials involving low-risk or mixed-risk populations…7,8 suggesting that tranexamic acid may have greater clinical utility in patients at high risk of PPH.”  
   **Problem:** The comparison with reference 7 is not accurate. TRAAP2 reported the same primary-outcome definition and found PPH in “556/2086 (26.7)” in the tranexamic acid group versus “653/2067 (31.6)” in placebo—an absolute difference of 4.9 percentage points, giving an NNT of about 20. The present manuscript reports 29.7% versus 35.1%, an absolute difference of 5.4 percentage points, NNT 19. That is very similar, not “substantially lower.” Reference 8 did have much smaller absolute differences for death/transfusion and estimated blood loss >1 L, but those outcomes were not statistically significant in the same way.  
   **Revision needed:** Revise the comparison. A fairer statement would be that the NNT for the primary composite is similar to TRAAP2 but lower than the absolute differences seen in the MFMU trial for death/transfusion or estimated blood loss >1 L. The inference that high-risk placenta praevia patients have “greater clinical utility” should be softened or supported by a formal comparative analysis.

4. **The cultural explanation for low hysterectomy rates is unsupported and should be cited or removed.**  
   **Manuscript location:** Discussion, p 12, lines 371–377: “First, influenced by Confucian values emphasising family continuity, families typically consent to hysterectomy only under clear and imminent maternal threat.”  
   **Problem:** This is a broad sociocultural causal explanation with no citation. It is also potentially sensitive and speculative. The same paragraph attributes the low hysterectomy rate to two “key factors,” but only the second factor is supported by trial data in the supplementary appendix.  
   **Revision needed:** Provide a relevant citation or revise this as a hypothesis based on local clinical experience, not as an established explanation.

## 3. Minor points

1. **Reference 1 title is inaccurate in the manuscript reference list.**  
   **Manuscript location:** Reference list, p 17: “World Health Organization. Roadmap for the prevention and management of postpartum haemorrhage (PPH).”  
   **Source:** The provided WHO document title and suggested citation are “A Roadmap to combat postpartum haemorrhage between 2023 and 2030.” This should be corrected.

2. **Reference 5 is uncheckable — source PDF not provided.**  
   **Manuscript location:** Introduction, p 6, line 151: “The prevalence of placenta praevia has been increasing in many countries,5…”  
   Because ref 5 was not provided, I could not verify this claim. Either provide the source or cite an available source.

3. **Reference 16 is uncheckable — source PDF not provided.**  
   **Manuscript location:** Methods, p 8, lines 232–235: surgical procedures “adhering to both Chinese guidelines16 and institutional protocols…”  
   This is relevant to clinical standardisation, but the source PDF was not provided.

4. **Reference 24 is only indirect support for the discussion of gravimetric underestimation.**  
   **Manuscript location:** Discussion, p 13, lines 397–399: “gravimetric estimation is inherently prone to underestimation… consistent with previous report24.”  
   **Source:** Reference 24 studied vaginal deliveries and compared quantitative blood loss using a collector bag with calculated blood loss. It concluded: “quantitative blood loss is lower than calculated blood loss,” and the median quantitative loss was 100 mL versus calculated 260 mL. This supports the general idea that measured/quantitative loss may be lower than calculated loss, but it is not specifically a gravimetric caesarean-delivery study in placenta praevia. The manuscript should either qualify the comparison or cite a more directly applicable source.

5. **The “low-risk or mixed-risk (~50% unscheduled caesarean delivery)” wording should specify which prior trial it describes.**  
   Reference 8 restricted randomization to a maximum of 50% scheduled caesareans and reported scheduled caesarean delivery in 50.1% and 49.2% of groups. Reference 7 reported caesarean delivery during labor in only 28.9% and 29.2%. The parenthetical “~50% unscheduled” applies to ref 8, not ref 7.

## 4. Anything you verified that checked out

1. **Global PPH burden from WHO is accurately supported.**  
   The manuscript states that PPH affects millions and accounts for >20% of maternal deaths. Reference 1 states: “It affects millions of women every year and accounts for over 20% of all maternal deaths reported globally.”

2. **The China placenta praevia prevalence trend is supported by ref 6.**  
   The manuscript states that prevalence in China nearly tripled after the universal two-child policy. Reference 6 reports that after the two-child policy, prevalence increased “from 1.25%… to 4.12%,” which supports the claim.

3. **The placenta praevia/low-lying placenta ultrasound classification is supported.**  
   The manuscript defines placenta praevia/low-lying placenta using the 2 cm threshold. References 3 and 14 both support this: ref 3 describes “placenta previa, where the placenta is covering the cervical os” and “low-lying placenta, where the placental edge is within 2 cm of the cervical os”; ref 14 likewise describes low-lying placenta as the edge “within 2 cm of the internal os.”

4. **PAS diagnostic criteria and post hoc review are consistent with FIGO classification.**  
   Reference 15 provides clinical and histologic criteria for PAS grades 1–3, including criteria applicable at laparotomy and after hysterectomy or partial myometrial resection. This supports the manuscript’s use of FIGO-based PAS diagnosis.

5. **The calculated blood-loss formula is supported by ref 19.**  
   The manuscript uses estimated blood volume = weight × 85 and calculated blood loss from pre/post haematocrit. Reference 19 gives the same formula: “estimated blood volume = booking weight (kg) × 85.”

6. **The MFMU tranexamic-acid trial is accurately cited for lack of effect on death/transfusion and higher postpartum infections.**  
   Reference 8 reports primary outcome maternal death or transfusion in 3.6% vs 4.3% (RR 0.89, 95.26% CI 0.74–1.07) and postpartum infectious complications in 3.2% vs 2.5% (RR 1.28, 95% CI 1.02–1.61), matching the manuscript’s discussion.

7. **The PAS proportion in this trial is higher than prior population estimates.**  
   The manuscript’s 17.9% PAS proportion among placenta praevia participants is higher than ref 22’s median PAS incidence among women with placenta previa of 11.10% and far higher than ref 21’s general-population PAS prevalence estimate of 0.17%.

8. **The low hysterectomy rate is broadly consistent with the two cited Chinese cohorts.**  
   Reference 4 reports 9 hysterectomies among 430 selected patients, and ref 23 reports hysterectomy in 2/201 women with placenta previa/low-lying placenta, supporting that hysterectomy rates around 1–2% have been reported in Chinese specialist settings.

## 5. Editorial recommendation

**Major revision.** The trial question is important and many core citations check out, but the manuscript’s rationale and interpretation need correction before publication. In particular, the placenta praevia/PAS PPH-incidence claim overgeneralises a selected cohort; the prior tranexamic-acid evidence is not characterised with enough nuance; and the NNT comparison with TRAAP2 is not supported. These issues do not necessarily invalidate the trial findings, but they could mislead readers about baseline risk, novelty, and comparative clinical utility.

## 6. What I could not assess

1. I could not verify any claim relying on **reference 5** because the source PDF was not provided. This affects the statement that placenta praevia prevalence has been increasing in many countries.  
2. I could not verify any claim relying on **reference 16** because the source PDF was not provided. This affects the statement that surgical procedures adhered to Chinese guidelines.  
3. I did not have raw data, analysis code, trial monitoring records, or case-report forms, so I could not independently verify the trial results, adverse-event ascertainment, or protocol adherence beyond what is reported in the manuscript.  
4. I focused on the 24 indexed manuscript references supplied. Some supplementary materials appear to list additional studies or protocol references whose PDFs were not part of the provided reference set, so I could not comprehensively check those non-indexed sources.

===== TOKENS =====
api_calls=41  input=3983891 (cached=3742720)  output=12504  (reasoning=6626)  total=3996395
est_cost: $3.45 (cached@$0.50/M) .. $20.29 (upper bound) | dashboard authoritative

===== END (2026-06-03T22:12:27) =====